Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
Launched by MASSACHUSETTS GENERAL HOSPITAL · Oct 16, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to help reduce the risk of suicide in individuals with major depressive episodes or borderline personality disorder. The treatment involves using a non-invasive device that sends magnetic pulses to a specific part of the brain to help improve mood and decrease suicidal thoughts and behaviors. Researchers are currently looking for participants between the ages of 18 and 65 who have been diagnosed with these mental health conditions and are experiencing suicidal thoughts.
If you or someone you know is interested in participating, it's important to know that not everyone will qualify. Eligible participants should not have certain neurological conditions, metal implants, or other medical issues that could interfere with the treatment or brain imaging tests. Those who join the trial can expect to receive this innovative therapy and be closely monitored throughout the study. This trial aims to better understand how this treatment works and how it can help individuals struggling with severe mental health challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18-65 years of age
- • Diagnosed with BPD or MDE
- • Chief complaint of suicidal thoughts and behaviors
- Exclusion Criteria:
- • Neurological conditions with known structural brain lesion
- • Prior neurosurgical procedure
- • Metal in the body that is ferromagnetic or metal injury to the eyes
- • Epilepsy
- • Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt
- • Psychopathology not appropriate for the treatment (e.g., manic episode or psychosis)
- • Current alcohol dependence or active symptoms of non-alcohol psychoactive substance use withdrawal, as indicated by self-report
- • Inability to meet the safety criteria for MRI scanning according to the protocols of the MGH Department of Radiology
- • Current pregnancy
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Joan Camprodon, MD/PhD
Principal Investigator
6177265348
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials